Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P4HB | P07237 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658659 | 0.90 | PPARA (0.64) | CYP1B1CYP1A1CYP1A2PPARACYP3A4 | |
| SCHEMBL10275039 | 0.87 | CYP1A1 (0.70) | CYP1B1CYP1A1CYP1A2PPARACYP3A4 | |
| SCHEMBL10275087 | 0.86 | RAB9A (0.66) | CYP1B1CYP1A1CYP1A2CYP3A4RAB9A | |
| SCHEMBL10309019 | 0.86 | RAB9A (0.66) | CYP1B1CYP1A1CYP1A2CYP3A4RAB9A | |
| SCHEMBL10275466 | 0.84 | CYP3A4 (0.62) | CYP1B1CYP1A1CYP1A2PPARACYP3A4 | |
| SCHEMBL27762189 | 0.82 | APP (0.57) | PPARACYP3A4RAB9AMGAMKDM4E | |
| SCHEMBL3394320 | 0.80 | CYP1B1 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17233430 | 0.80 | CYP1B1 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10309037 | 0.79 | CYP1A1 (0.70) | CYP1B1CYP1A1CYP1A2CYP3A4RAB9A | |
| SCHEMBL10275040 | 0.79 | CYP1A1 (0.70) | CYP1B1CYP1A1CYP1A2CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230312728-A1 | Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4200016-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040161-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2017208174-A2 | METHODS OF TREATING DISEASE WITH PFKFB3 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | WO | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | CYP1B1 4552/4885CYP1A1 4826/4885CYP1A2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.